Research programme: antituberculars - AstraZenecaAlternative Names: Tuberculosis therapies - AstraZeneca/Global Alliance for TB Drug Development
Latest Information Update: 05 May 2010
At a glance
- Originator AstraZeneca
- Mechanism of Action Phosphotransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 03 May 2010 AstraZeneca and The Global Alliance for TB Drug Development agree to co-develop drugs for Tuberculosis
- 15 Sep 2009 Antimicrobial data from preclinical studies in tuberculosis presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
- 28 Mar 2008 Preclinical development is ongoing